Pelthos Q4 ZELSUVMI sales $9.1M, up 28% QoQ; adds XEPI and XEGLYZE

Pelthos Therapeutics Inc.

ZELSUVMI net product revenue $9.1M in Q4 2025 vs $7.1M in Q3; full-year 2025 total revenue $16.8M.
8,948 units dispensed, 2,712 unique prescribers; Q4 units up 129% QoQ to 6,232.
Acquired XEPI (impetigo) Nov 2025 and XEGLYZE (head lice) Jan 2026; sales force expanded to 64.
Closed $18M convertible notes Nov 2025 and $50M term loan ($30M drawn) Jan 2026; cash $18M at year-end.
Operating loss improved to $12M in Q4 from $15.4M in Q3; adjusted EBITDA loss improved 22% QoQ.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pelthos Therapeutics Inc. reported financial results for fourth quarter and full year ended December 31, 2025.

Period: fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

Pelthos Therapeutics Inc. (the “Company”) issued a press release summarizing its financial results for the three months and year ended December 31, 2025

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Pelthos Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001919246-26-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.